Masimo Receivables 2010-2025 | MASI

Masimo receivables for the quarter ending March 31, 2025 were $286M, a 13.52% decline year-over-year.

  • Masimo receivables for 2024 were $0.427B, a 19.97% increase from 2023.
  • Masimo receivables for 2023 were $0.356B, a 20.27% decline from 2022.
  • Masimo receivables for 2022 were $0.446B, a 122.06% increase from 2021.

Masimo Receivables 2010-2025 | MASI

  • Masimo receivables for 2024 were $0.427B, a 19.97% increase from 2023.
  • Masimo receivables for 2023 were $0.356B, a 20.27% decline from 2022.
  • Masimo receivables for 2022 were $0.446B, a 122.06% increase from 2021.
Related Stocks
Company NameMarket
Cap
Thermo Fisher Scientific (TMO)$183.1B
Intuitive Surgical (ISRG)$177.1B
Edwards Lifesciences (EW)$46B
IDEXX Laboratories (IDXX)$45.6B
Alcon (ALC)$44.5B
DexCom (DXCM)$35.1B
IQVIA Holdings (IQV)$33.6B
Mettler-Toledo (MTD)$26.2B
STERIS (STE)$22.3B
Waters (WAT)$18B
SONOVA HOLDING (SONVY)$17.3B
Hologic (HOLX)$14.6B
Sysmex ADR (SSMXY)$10.6B
Penumbra (PEN)$8.9B
Globus Medical (GMED)$7.4B
Glaukos (GKOS)$5.4B
Teleflex (TFX)$5.1B
Integer Holdings (ITGR)$3.8B
TransMedics (TMDX)$3.6B
PROCEPT BioRobotics (PRCT)$3B
LivaNova (LIVN)$2.4B
Veracyte (VCYT)$2B
Elekta AB (EKTAY)$1.9B
Nihon Kohden (NHNKY)$1.9B
Alphatec Holdings (ATEC)$1.6B
Artivion (AORT)$1.3B
Tandem Diabetes Care (TNDM)$1.1B
Paragon 28 (FNA)$1.1B
OPKO Health (OPK)$1.1B
Pulse Biosciences (PLSE)$1B